Previous investigations have revealed that bladder cancer cells are generally resistant to Fas-mediated apoptosis by conventional Fas agonists. However, the ability of these cell lines to undergo Fas-mediated apoptosis may have been underappreciated. As a result, we investigated the in vitro efficacy of Fas ligand gene therapy for bladder cancer. Three human bladder cancer lines (T24, J82, and 5637) were treated with the conventional Fas agonist CH-11, a monoclonal antibody to the Fas receptor. Cells were also treated with a replication-deficient adenovirus containing a modified murine Fas ligand gene fused to green fluorescent protein (GFP), AdGFPFasL. A virus containing the GFP gene alone was used to control for viral toxicity (AdGFP). Cell death was quantified using a tetrazolium-based (MTS) assay. Cells were also evaluated by Western blotting to evaluate poly (ADP-ribose) polymerase, caspase 8, and caspase 9 cleavage and by flow cytometry to determine the presence of coxsackie/adenovirus receptor (CAR). These studies confirmed bladder cancer resistance to cell death by the anti-Fas monoclonal antibody CH-11. This resistance was overcome with AdGFPFasL at a multiplicity of infection (MOI) of 1000 achieving over 80% cell death in all cell lines. Furthermore, greater than 80% cell death was evident in 5637 cells treated with low-dose AdGFPFasL (MOI ¼ 10). 5637 cells expressed significantly higher levels of surface CAR than J82 or T24 cells (Po.05). AdGFPFasL is cytotoxic to bladder cancer cells that would otherwise be considered Fas resistant, supporting its in vivo potential. Enhanced sensitivity to AdGFPFasL may be in part due to increased cell surface CAR levels. Cancer Gene Therapy ( Keywords: apoptosis B ladder cancer is the second most-common cancer of the genitourinary tract. Currently, there are a wide range of therapeutic modalities available based on the extent of the disease including intravesical chemotherapy, surgery, radiation therapy, and systemic chemotherapy. Unfortunately, patients with advanced bladder cancer face a 5-year survival rate of approximately 20-40% despite the wide range of treatment modalities.
B
ladder cancer is the second most-common cancer of the genitourinary tract. Currently, there are a wide range of therapeutic modalities available based on the extent of the disease including intravesical chemotherapy, surgery, radiation therapy, and systemic chemotherapy. Unfortunately, patients with advanced bladder cancer face a 5-year survival rate of approximately 20-40% despite the wide range of treatment modalities. 1, 2 As a result of the shortcomings of current treatments, there is clearly a need for investigation into new treatment modalities.
Multiple investigators have reported on gene therapybased strategies to treat cancer. Recently, several groups have focused on the potential of members of the tumor necrosis factor (TNF) family, including TNF-a, TNFrelated apoptosis-inducing ligand (TRAIL), and Fas ligand (FasL) , that are known to induce apoptosis in a variety of sensitive and resistant cell types. In this report, we investigate the potential of FasL gene therapy for the treatment of bladder cancer.
FasL (CD95L or APO-1L) is a 40-kDa type II membrane protein belonging to the TNF family. 3 FasL interacts with its receptor, Fas (CD95 or APO-1), which is a member of the TNF/NGF (nerve growth factor) superfamliy of membrane receptors. 4 These receptors are known to contain a death domain integral to transduction of the apoptotic signal following receptorligation. 5 Several groups have investigated the potential utility of the Fas system in the treatment of cancer. These studies have activated the Fas receptor in a variety of ways. While some studies have utilized a soluble form of FasL, 6 other studies have used monoclonal antibodies against Fas that act as agonists. 7, 8 Lastly, delivery of the FasL gene has also been attempted by multiple investigators in other cell types including glioblastoma and prostate cancer. [9] [10] [11] The purpose of this study was to determine the cytotoxic potential of a gene therapy for bladder cancer utilizing a replication-deficient adenovirus to deliver a green fluorescent protein-FasL fusion gene (GFPFasL).
In addition, we provide data that suggest that the vector delivery system may be just as important as the transgene delivered when determining the efficacy of gene therapy approaches for the treatment of bladder cancer.
Materials and methods

Cell lines and culture
The bladder cancer cells lines 5637 and J82 were purchased from the American Type Culture Collection (Rockville, MD). The bladder cancer line T24 was a kind gift from Dr Tim Vincent (Medical University of South Carolina, Charleston, SC). Jurkat cells were a kind gift from Dr Yusuf Hannun (Medical University of South Carolina, Charleston, SC). All cell lines were maintained in RPMI 1640 medium (Gibco-BRL, Carlsbad, CA) supplemented with heat-inactivated 10% fetal bovine serum (Hyclone, Logan, UT).
Reagents
Construction and preparation of the viral vectors AdGFPFasL and AdGFP are previously described.
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The mouse anti-Fas monoclonal antibody CH-11 (Kamiya Biochemical, Seattle, WA) was used as a Fas agonist. Antibodies for immunoblotting and concentrations used are as follows: anti-rabbit IgG-HRP (horseradish peroxidase) conjugated (1:50,000; Santa Cruz Biotechnology, Santa Cruz, CA), anti-mouse IgG-HRP conjugated (1:5000; Sigma-Aldrich, St Louis, MO), mouse monoclonal anti-caspase 8 (1:1000; Alexis Biochemicals, San Diego, CA), rabbit polyclonal anticaspase 9 (1:1000; Cell Signaling Technology, Beverly, MA), rabbit polyclonal anti-actin (1:2000; Sigma-Aldrich), and rabbit polyclonal anti-poly (ADP-ribose) polymerase (PARP) (1:2500; Santa Cruz Biotechnology, Santa Cruz, CA). Caspase 3/7 fluorescence assay Cells were seeded as described above in clear bottom black 96-well plates (Corning, Acton, MA). At 24 hours after seeding, medium was removed and replaced with medium only or medium containing AdGFP or AdGFPFasL vectors at an MOI of 250 (J82 and T24) or 100 (5637). After 24 hours of treatment, caspases 3 and 7 activities were measured using Apo-ONE Homogeneous caspase 3/7 assay according to the manufacturer's instructions (Promega, Madison, WI). Fluorescence was measured using a Fluostar Galaxy dual fluorescence/ absorbance plate reader (BMG Laboratories, Durham, NC) with 485 nm excitation and 520 nm emission filter set.
Cytotoxicity assays
Flow cytometry for quantification of GFP expression
Bladder cells were plated at 3 Â 10 5 (5637/T24) or 1.34 Â 10 5 /well (J82) overnight in six-well plates. The next day, medium was removed and virus (AdGFP TET , previously described 13 ) added in 1 ml serum-free RPMI for 3 hours. Then 1 ml RPMI containing 10% FBS and 10 mg/ml doxycycline was added. At 24 hours postinfection, cells were trypsinized and analyzed by flow cytometry for GFP expression, using a FACSCalibur (Becton-Dickinson, Bedford, MA). A minimum of 10,000 events was scored for each sample. 
Statistics
The Student's t-test was used to determine the statistical significance of data. A P-value of 0.05 or less was considered significant. Data presented in graphs and figures represent the mean7standard deviation (SD).
Results
Bladder cancer cells are relatively resistant to CH-11-induced cell death
We examined the susceptibility of three human bladder cancer cell lines to apoptosis via CH-11, a monoclonal antibody to Fas with agonistic properties. Cells were treated with CH-11 at a concentration of 1 mg/ml, and cytotoxicity was determined after 48 hours. The T-cell leukemia line Jurkat was used as a positive control. Figure 1 confirms that Jurkat cells were extremely susceptible to CH-11-induced death with greater than 90% cell death after 48 hours. Jurkat cells were significantly more sensitive to CH-11 than all three bladder cancer lines tested (Po0.05). The bladder cell lines T24 and 5637 were mildly sensitive to CH-11-induced death with cytotoxicity at approximately 40 and 30%, respectively. Previous reports on the cell line T24 have also shown the relative resistance of this cell line to CH-11-induced cell death at a similar concentration.
14 Noteworthy was the resistance of J82 to CH-11-induced apoptosis with almost no detectable cell death after 48 hours of treatment.
Adenoviral delivery of GFPFasL is cytotoxic to bladder cancer cells
We next determined the sensitivity of the bladder cancer cell lines to AdGFPFasL. Cells were treated for 48 hours with an MOI of 10, 100, and 1000 with either AdGFPFasL virus or control virus (AdGFP). Again, cytotoxicity was determined using the MTS assay. As shown in Figure 2 , all three cell lines were sensitive to AdGFPFasL as compared to control virus. In fact, cell death following AdGFPFasL was significantly higher than AdGFP treatment (Po0.05) for all cell lines at all MOIs tested except for J82 cells at an MOI of 10 (P ¼ 0.06). In addition, there was a proportional increase in cell death with increasing MOI. The cell line J82, which was completely resistant to CH-11-induced cell death, displayed greater than 80% cytotoxicity with an MOI of 1000 with negligible cytotoxicity following control virus treatment. Similar results are shown for T24 cells with cytotoxicity approaching 95% following treatment with AdGFPFasL at an MOI of 1000. Again, negligible cytotoxicity was seen in this cell line following treatment with the control virus. Of interest are the results obtained with the cell line 5637, which were extremely sensitive to AdGFPFasL. Following AdGFPFasL treatment at an MOI of 10, 5637 cells displayed 80% cytotoxicity. On the other hand, J82 and T24 were only 20% cytotoxic at a similar MOI. In addition, 5637 cells were partially sensitive to AdGFP treatment with greater than 40% cytotoxicity noted at an MOI of 1000. 
AdGFPFasL induces characteristics consistent with Fasmediated apoptosis
Both morphological and biochemical analyses were performed to determine if treatment of bladder cancer cells with AdGFPFasL is consistent with Fas-mediated apoptosis. Figure 3 shows J82 bladder cancer cells with various treatments at 48 hours under both light and UV (ultraviolet) microscopy. Untreated cells were spread out and grew as a smooth monolayer adherent to the bottom of the tissue culture dish. No cells were visualized under UV microscopy, consistent with lack of GFP expression. J82 cells treated with AdGFP under light microscopy displayed a similar architecture as untreated cells. However, UV microscopy revealed green cells, consistent with successful transduction and expression of the GFP gene. Lastly, J82 cells treated with AdGFPFasL for 48 hours were round and aggregated. Furthermore, these cells were mostly detached from the tissue culture plate and were floating indicating cell death. Under UV microscopy, green cells were visualized, confirming successful expression of the GFPFasL fusion gene. Biochemical analyses were also consistent with apoptosis. Protein lysates were collected from cells at various time points for untreated, AdGFP-treated, and AdGFPFasLtreated cells. The lysates were then subjected to Western blot analysis for caspase 8, 9, and PARP and a fluorometric assay for caspase 3 and 7. Caspase 8 is the most proximal caspase in the Fas-mediated apoptotic pathway. 15 Cells treated with AdGFPFasL have clear evidence of caspase 8 cleavage as seen by the reduction in procaspase 8 zymogens (p53 and p55) and appearance of intermediate (p43 and p41) and active (p18) fragments (Fig 4a) . There is also clear evidence of caspase 9 cleavage following treatment with AdGFPFasL (Fig 4a) , indicating involvement of the apoptosome in the transduction of the death signal. 16 In addition, cell lysates from all three cell lines treated with AdGFPFasL have high activity levels of the executioner caspases 3 and 7 compared to untreated and control-virus treated cells as determined by fluorometric caspase assay (Fig 4b) . Furthermore, there is clear evidence of PARP cleavage. PARP is a nuclear enzyme whose activity is increased in response to cellular DNA damage. Cleavage of PARP by effector caspases, from a 116-kDa protein to an 85-kDa fragment, is thought to be a marker of apoptosis. 17 The antibody utilized for Western blotting is capable of detecting both full-length and cleaved PARP. As seen in Figure 4c , all three bladder cancer lines underwent significant PARP cleavage following treatment with AdGFPFasL. No PARP cleavage was detected in untreated cells (first column) or AdGFP-treated cells, consistent with lack of cytotoxic effect.
cells have enhanced expression of the coxsackieadenovirus receptor
5637 cells were clearly more sensitive to AdGFPFasL than J82 and T24 as shown in Figure 2 . 5637 cells appeared to be more sensitive to viral infection based on two observations. First, AdGFP was toxic to 5637 cells at a high MOI but nontoxic to J82 and T24 cells (Fig 2) . In addition, 5637 cells appeared to express more GFP under UV microscopy than J82 and T24 cells when treated with AdGFP at a similar MOI (Fig 5a) . This observation was confirmed by flow cytometry indicating that following infection with an adenovirus containing the GFP gene, 5637 cells had a higher percentage of cells that were GFP (Fig 5b) . In addition, 5637 cells that were GFPpositive based on flow cytometry had higher fluorescence intensities than either J82 or T24 cells (Fig 5c) . Adenoviral binding to the cell surface is a receptordependant event. CAR is a 46-kDa protein endogenously present on human cells that is responsible for the binding of group C adenoviruses. 18, 19 A previous investigation by Li et al 20 reported CAR expression on human bladder cancer lines that correlates with susceptibility to viral infection. As a result of these findings, we determined the levels of CAR expression on 5637, J82, and T24 cells using flow cytometry (Fig 6) and confirmed that 5637 cells have a significantly higher percentage of cells expressing cell surface CAR compared to T24 or J82 cells (Po0.05). Hence, 5637 cells appear to be more sensitive to both viral infection and AdGFPFasL treatment. Of note, the low level of observed CAR expression on T24 cells is consistent with prior data. 20 
Discussion
In this report, we have characterized the in vitro efficacy of a gene therapy-based approach for the treatment of bladder cancer. We have demonstrated extensive cytotoxicity following treatment with AdGFPFasL in bladder cancer cells that would otherwise be considered Fas resistant. Furthermore, we have confirmed that surface levels of CAR may heavily impact the efficacy of adenoviral-based gene therapy strategies.
Several previously published reports have investigated the utilization of the Fas system to induce apoptosis in tumor cells ranging from brain tumor cells to prostate cancer cells. [9] [10] [11] Investigation by Mizutani et al revealed that the established bladder cancer cell line T24 was resistant to apoptosis following treatment with Fas agonistic antibody, CH-11. However, T24 cells were sensitized to Fas-mediated cytotoxicity by CH-11 following cotreatment with either doxorubicin or cisplatin plus 5-fluorouracil. 14, 21 Furthermore, T24 cells were also found to be resistant to recombinant Fas ligand. 22 These studies in addition to others have led to the characterization of some cancer cell lines such as T24 as Fas resistant despite the presence of Fas on the cell surface with a variety of proposed mechanisms for this resistance. Prior analysis of cell death in prostate cancer cells has shown that AdGFPFasL downregulates the antiapoptotic protein c-FLIP (cellular Flice-like inhibitory protein). 12 While beyond the scope of the current investigation, downregulation of c-FLIP may also account for the observed sensitivity in bladder cancer cells.
While the FasL gene appears to be capable of inducing cell death in bladder cancer cells, the CAR data indicate the importance of vector delivery as well. While type 5 adenovirus (used in the experiments presented) is widely infectious, it is clear that cells vary in their ability to undergo infection. This is in concordance with previous data. 20 Our findings also indicate that other factors may determine susceptibility to adenoviral infection. For example, T24 cells have low levels of surface CAR despite having a high number of GFP-expressing cells following infection with AdGFP (Fig 4) . This may be due to expression of CAR at levels below the threshold of detection by RcmB. Alternatively, it could indicate that other receptors are responsible for adenoviral entry. Recent data have implicated integrin a3b1 as an alternate receptor for serotype 5 adenovirus, which is the same serotype used in the experiments presented here. 23 Future strategies may need to enhance infectivity of cells or consider other methods of gene delivery to augment efficacy.
Although gene therapy has been proposed for a variety of malignancies, bladder cancer may be especially AdGFPFasL induces activation of executioner caspases. Cells were treated as described above. At 24 hours after infection, caspases -3 and -7 activities were determined using a caspase 3/7 fluorometric assay. (c) AdGFPFasL induces PARP cleavage. Cells were infected with AdGFP or AdGFPFasL as described above and protein was harvested at the indicated time points. Protein lysates were then subjected to immunoblotting analysis to detect both full-length and cleaved PARP. There has been published data to suggest that the protective glycosaminoglycan layer is diminished in areas of tumor in a murine model of bladder cancer. 24 Hence, tumorigenic areas may be more susceptible to viral infection. However, selection for tumorigenic areas over normal uroepithelium cannot be assured based on the experiments presented in this study. Nevertheless, current management for superficial cancers of the bladder includes use of intravesical agents such as Bacille Calmette-Gue´rin (BCG) and mitomycin, which have known local toxicities. 25 However, their toxicities are considered acceptable in the context of their proven therapeutic benefit in the treatment and prevention of bladder cancer. The same may hold true for AdGFPFasL. Furthermore, newer agents such as interferon-a2B, which is synergistic with BCG, have allowed for the development of treatment protocols that are less toxic while maintaining efficacy. 26 Studies are ongoing to assess synergy of AdGFPFasL with other potential intravesical agents. One potential disadvantage of intravesical administration of AdGFPFasL is limited tissue penetration. However, this laboratory has identified the existence of bystander effect with AdGFPFasL in prostate cancer cells that may allow for toxicity in cells that have not undergone active infection. 27 Current investigation is examining whether a similar phenomenon occurs in bladder cancer cells following treatment with AdGFPFasL.
Conclusion
While bladder cancer is a relatively common disease, effective treatments for local as well as advanced disease are still lacking. Indeed, there are several unique aspects Fas ligand gene therapy for bladder cancer S Sudarshan et al of bladder cancer that may make it more amenable to a gene therapy-based approach. Here, we have identified three bladder cancer lines that are Fas resistant and sensitive to a virally delivered modified murine Fas ligand gene. The morphologic and intracellular changes following treatment are consistent with Fas-mediated apoptosis. Furthermore, the data presented here demonstrate that the efficacy of gene therapy relies on the transgene delivered as well as on the method of delivery. Clearly, future studies will need to focus on in vivo efficacy to determine the potential role of this agent in the treatment of local as well as invasive bladder cancers.
